SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Mercoledì 14 luglio 2021
circa 1 minuti di lettura
Journal and Affiliations:
Nature, 14 luglio 2021
Fabrizia Zatta, Humabs BioMed, Bellinzona
Dora Pinto, Humabs BioMed, Bellinzona
Martina Beltramello, Humabs BioMed, Bellinzona
Roberta Marzi, Humabs BioMed, Bellinzona
Anna De Marco, Humabs BioMed, Bellinzona
Jessica Bassi, Humabs BioMed, Bellinzona
Chiara Silacci Fregni, Humabs BioMed, Bellinzona
Gloria Lombardo, Humabs BioMed, Bellinzona
Nicole Sprugasci, Humabs BioMed, Bellinzona
Katja Culap, Humabs BioMed, Bellinzona
Stefano Jaconi, Humabs BioMed, Bellinzona
Elisabetta Cameroni, Humabs BioMed, Bellinzona
Luca Piccoli, Humabs BioMed, Bellinzona
Fabio Benigni, Humabs BioMed, Bellinzona
Matteo Samuele Pizzuto, Humabs BioMed, Bellinzona
Davide Corti, Humabs BioMed, Bellinzona
Tags:
antibody therapeutics
SARS-CoV-2
Authors:
Anna De Marco
Chiara Silacci Fregni
Davide Corti
Dora Pinto
Elisabetta Cameroni
Fabio Benigni
Fabrizia Zatta
Gloria Lombardo
Jessica Bassi
Katja Culap
Luca Piccoli
Martina Beltramello
Matteo Samuele Pizzuto
Nicole Sprugasci
Roberta Marzi
Stefano Jaconi